scholarly journals Real-World Patterns and Implications of Short-Acting Beta2-Agonist Use in Patients with Asthma in the USA

2021 ◽  
Author(s):  
Njira Lugogo ◽  
Ileen Gilbert ◽  
Joseph Tkacz ◽  
Hitesh Gandhi ◽  
Nadia Goshi ◽  
...  
Keyword(s):  
Real World ◽  
Short Acting ◽  
The Usa ◽  
Beta2 Agonist

Fr201 PERSISTENCE OF ABNORMAL ENDOSCOPY AND BIOPSY FINDINGS IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS IN A REAL-WORLD SETTING IN THE USA

2021 ◽  
Vol 160 (6) ◽  
pp. S-263-S-264
Author(s):  
Olulade Ayodele ◽  
Rohan C. Parikh ◽  
Elizabeth Esterberg ◽  
Mayank Ajmera ◽  
Bridgett Goodwin ◽  
...  
Keyword(s):  
Eosinophilic Esophagitis ◽  
Real World ◽  
Real World Setting ◽  
The Usa

Pesticides in Honey Bee Colonies: establishing a baseline for real world exposure over seven years in the USA

2021 ◽  
pp. 116566
Author(s):  
Kirsten S. Traynor ◽  
Simone Tosi ◽  
Karen Rennich ◽  
Nathalie Steinhauer ◽  
Eva Forsgren ◽  
...  
Keyword(s):  
Honey Bee ◽  
Real World ◽  
The Usa ◽  
Bee Colonies

scholarly journals Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database

2021 ◽  
Author(s):  
Annette Rudolph ◽  
Hendrike Dahmke ◽  
Hugo Kupferschmidt ◽  
Andrea Burden ◽  
Stefan Weiler
Keyword(s):  
Real World ◽  
Safety Issue ◽  
Demographic Data ◽  
Fatal Outcome ◽  
Individual Case ◽  
World Health ◽  
Global Database ◽  
The Usa ◽  
Pharmacovigilance Database ◽  
The Impact

Abstract Purpose Tizanidine, an alpha-adrenergic substance with antinociceptive and antihypertensive effects, is extensively metabolized via cytochrome P450 (CYP) 1A2. Therefore, coadministration with potent CYP1A2 inhibitors, such as ciprofloxacin, is contraindicated. However, both drugs are broadly utilized in various countries. Their concomitant use bears an inherent high risk for clinically significant symptoms, especially in multimorbid patients experiencing polypharmacy. This study aims to investigate the impact of coadministration of tizanidine and ciprofloxacin using real-world pharmacovigilance data and to raise awareness of this potentially underestimated safety issue. Methods We conducted a retrospective study including Individual Case Safety Reports (ICSR) registered until March 1, 2017, in the World Health Organization (WHO) global database. Demographic data, drug administration information, the course of the adverse drug reaction (ADR), its severity, and outcomes were analyzed for cases reporting ciprofloxacin comedication. Results In 91 (2.0%) of the identified 4192 worldwide ICSR on tizanidine, coadministration of ciprofloxacin was reported. Most of the patients were female (n = 59, 64.8%) with a median age of 54 years (range 13–85 years). The countries contributing most reports were the USA (n = 54, 59.3%) and Switzerland (n = 16, 17.6%). ADRs reported most often affected the nervous system and the cardiac function, especially with large tizanidine doses or drugs with CNS and cardiovascular depressant effects. In two cases, a fatal outcome was reported. Conclusion Despite the existing formal contraindication, the concomitant use of tizanidine and ciprofloxacin can be observed in real-world clinical practice. Reactions mainly affected the central nervous and the cardiovascular system resulting in potentially severe adverse effects. The concomitant use of tizanidine and ciprofloxacin should absolutely be avoided.

scholarly journals Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA

2016 ◽  
Vol 70 (12) ◽  
pp. 1012-1018 ◽  
Author(s):  
John P. Mulhall ◽  
Xuemei Luo ◽  
Kelly H. Zou ◽  
Vera Stecher ◽  
Aaron Galaznik
Keyword(s):  
Erectile Dysfunction ◽  
Observational Data ◽  
Real World ◽  
The Usa

scholarly journals Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA

2015 ◽  
Vol 4 ◽  
pp. 1-12 ◽  
Author(s):  
Allicia Girvan ◽  
Gebra Carter ◽  
Li Lin ◽  
Anna Kaltenboeck ◽  
Jasmina Ivanova ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Resource Use ◽  
Real World ◽  
Healthcare Resource ◽  
Treatment Patterns ◽  
Healthcare Resource Use ◽  
The Usa

scholarly journals Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel

2021 ◽  
Author(s):  
Charles Lance Cowey ◽  
Frank X Liu ◽  
Ruth Kim ◽  
Marley Boyd ◽  
Nicole Fulcher ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Merkel Cell Carcinoma ◽  
Real World ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Response Rates ◽  
Merkel Cell ◽  
First Line ◽  
The Usa

Aim: To assess clinical outcomes in patients with locally advanced (la) or metastatic (m) Merkel cell carcinoma (MCC) initiating first-line (1L) avelumab in a USA community oncology setting. Materials & methods: Adults with laMCC or mMCC initiating 1L avelumab were identified from The US Oncology Network electronic health record database and chart review. Results: Median overall survival and progression-free survival were not reached in laMCC (n = 9) vs 20.2 and 10.0 months in mMCC (n = 19); response rates were similar (66.7% vs 63.2%). Conclusion: This is the first study to show clinical benefit in patients with laMCC receiving 1L avelumab in a US real-world setting. Response rates in patients with mMCC were consistent with pivotal trials.

Sign in / Sign up

Export Citation Format

Share Document